NEI Podcast E242- (CME) Past, Present, and Future: Muscarinic-Targeting Treatments for Schizophrenia
Nov 27, 2024
Dr. Jonathan M. Meyer, a Voluntary Clinical Professor at UC San Diego and psychopharmacology expert, discusses the evolution of muscarinic-targeting treatments for schizophrenia. He highlights the historical shifts from dopamine-centric therapies to the promising role of muscarinic receptors. Key topics include the challenges and innovations in cognitive impairment management, new drugs like xanomeline-trospium, and the impact of neurotransmitter interactions. Meyer emphasizes tailored treatment approaches and the importance of individualized dosing strategies for enhancing patient outcomes.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7
Intro
00:00 • 2min
Evolving Treatments for Schizophrenia
01:55 • 5min
Targeting Muscarinic Receptors in Schizophrenia Treatment
06:47 • 16min
Innovative Insights into Schizophrenia Treatments
22:52 • 16min
Dosing Strategies and Evolving Treatments for Schizophrenia
39:22 • 2min
Innovations in Antipsychotic Treatment
41:43 • 16min
Exciting Developments in Schizophrenia Treatment
58:11 • 2min